US equities |
NVDA $237.95 ▲+1.71% SPCX $167.85 ▲+5.60% MU $1,062.18 ▼-1.18% TSLA $379.17 ▲+2.32% MSFT $525.25 ▲+1.49% SNDK $1,710.00 ▼-0.58% INTC $116.86 ▼-2.07% META $742.46 ▲+1.98%
FinancialContent

Articles published by AlloVir, Inc.

News headline image
AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports Third Quarter 2023 Financial Results
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Present at Upcoming Investor Conferences
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports Second Quarter 2023 Financial Results
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Announces Pricing of Public Offering of Common Stock
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Announces Proposed Public Offering of Common Stock
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Present at the BofA Securities 2023 Health Care Conference
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Participate in the SVB Securities Global Biopharma Conference
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports Third Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports Second Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Announces $126.6 Million Registered Direct Offering
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir Reports First Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta
From AlloVir, Inc.
Via Business Wire
Tickers ALVR
News headline image
AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
From AlloVir, Inc.
Via Business Wire
Tickers ALVR